Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72940 record(s)

Req # A-2019-001924

Adverse Reaction Report (AER) for Mesalazine. Report numbers: E2B_02776457, 000730742, 000730734.

Organization: Health Canada

15 page(s)
June 2020

Req # A-2019-002012

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-122779-892, OVERVIEW OF CANNABIS PRODUCTS PERMITTED FOR SALE.

Organization: Health Canada

9 page(s)
June 2020

Req # A-2019-002027

Adverse Reaction Report (AER). Report number: 000733211.

Organization: Health Canada

12 page(s)
June 2020

Req # A-2019-002081

Adverse Reaction Report (AER). Report numbers: E2B_02893727, E2B_02895533, E2B_02916646.

Organization: Health Canada

55 page(s)
June 2020

Req # A-2020-000005

Adverse Reaction Report (AER) for HYDROXYCHLOROQUINE SULFATE. Report numbers: E2B_02266424, E2B_02502592, E2B_02263289, E2B_02569479, E2B_02521865.

Organization: Health Canada

87 page(s)
June 2020

Req # A-2020-000034

Adverse Reaction Report (AER). Report number: E2B_02876672.

Organization: Health Canada

32 page(s)
June 2020

Req # A-2020-000051

Adverse Reaction Report (AER) for ENTYVIO. Report numbers: E2B_02968814, E2B_02935743, E2B_02935720, E2B_02980774, E2B_02928576, E2B_02931979, E2B_02928948, E2B_02971530, E2B_02982966, E2B_02935644, E2B_02955576, E2B_02987178.

Organization: Health Canada

182 page(s)
June 2020

Req # A-2020-000052

Adverse Reaction Report (AER) for VEDOLIZUMAB. Report numbers: E2B_02959635, E2B_02972254, E2B_02931989, E2B_02965282, E2B_02983115, E2B_02973212, E2B_02940189, E2B_02975948, E2B_02928892.

Organization: Health Canada

120 page(s)
June 2020

Req # A-2020-000087

Adverse Reaction Report (AER). Report number: 000730668.

Organization: Health Canada

8 page(s)
June 2020

Req # A-2020-000190

Adverse Reaction Report (AER) for Teriflunomide. Report number: E2B_02548709.

Organization: Health Canada

6 page(s)
June 2020
Date modified: